These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 34962628)

  • 1. Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER.
    Takahara M; Mita T; Katakami N; Wada F; Morita N; Kidani Y; Yajima T; Shimomura I; Watada H;
    Diabetes Ther; 2022 Feb; 13(2):251-264. PubMed ID: 34962628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan-A Protocol.
    Katakami N; Mita T; Takahara M; Hashigami K; Kawashima M; Shimomura I; Watada H;
    Diabetes Ther; 2018 Feb; 9(1):165-175. PubMed ID: 29260460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study.
    Katakami N; Mita T; Takahara M; Yajima T; Wada F; Kawashima M; Shimomura I; Watada H;
    Diabetes Ther; 2020 Jul; 11(7):1563-1578. PubMed ID: 32504219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic control and incidence of hypoglycaemia, hospitalisation and complications among Saudi patients with type 2 diabetes initiating second-line therapy: an analysis of the Saudi Arabia data from the DISCOVER Observational Study programme.
    Al Rubeaan K; Banah F; Alruwaily FG; Sheshah E; Alnaqeb D; AlQahtani AM; Ewais D; Al Juhani N; Hassan AH; Youssef AM
    BMJ Open; 2023 Aug; 13(8):e063586. PubMed ID: 37648382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
    Khunti K; Chen H; Cid-Ruzafa J; Fenici P; Gomes MB; Hammar N; Ji L; Kosiborod M; Pocock S; Shestakova MV; Shimomura I; Tang F; Watada H; Nicolucci A;
    Diabetes Obes Metab; 2020 Jan; 22(1):66-78. PubMed ID: 31468637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review.
    Winkley K; Upsher R; Stahl D; Pollard D; Kasera A; Brennan A; Heller S; Ismail K
    Health Technol Assess; 2020 Jun; 24(28):1-232. PubMed ID: 32568666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment.
    Mita T; Katakami N; Takahara M; Kawashima M; Wada F; Akiyama H; Morita N; Kidani Y; Yajima T; Shimomura I; Watada H
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2424-2432. PubMed ID: 35857060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
    Charbonnel BH; Chen H; Cid-Ruzafa J; Cooper A; Fenici P; Gomes MB; Saraiva GL; Medina J; Nicolucci A; Shestakova MV; Shimomura I; Surmont F; Tang F; Vora J; Watada H; Khunti K;
    Diabetes Obes Metab; 2023 Jan; 25(1):46-55. PubMed ID: 36111434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Inertia and 2-Year Glycaemic Trajectories in Patients with Non-Newly Diagnosed Type 2 Diabetes Mellitus in Primary Care: A Retrospective Cohort Study.
    An LW; Li XL; Chen LH; Tang H; Yuan Q; Liu YJ; Ji Y; Lu JM
    Patient Prefer Adherence; 2021; 15():2497-2508. PubMed ID: 34795477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Inertia in Poorly Controlled Type 2 Diabetes Mellitus Patients with Obesity: An Observational Retrospective Study.
    Romera I; Díaz S; Sicras-Mainar A; López-Simarro F; Dilla T; Artime E; Reviriego J
    Diabetes Ther; 2020 Feb; 11(2):437-451. PubMed ID: 31884573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structured, intensive education maximising engagement, motivation and long-term change for children and young people with diabetes: a cluster randomised controlled trial with integral process and economic evaluation - the CASCADE study.
    Christie D; Thompson R; Sawtell M; Allen E; Cairns J; Smith F; Jamieson E; Hargreaves K; Ingold A; Brooks L; Wiggins M; Oliver S; Jones R; Elbourne D; Santos A; Wong IC; O'Neill S; Strange V; Hindmarsh P; Annan F; Viner R
    Health Technol Assess; 2014 Mar; 18(20):1-202. PubMed ID: 24690402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
    Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
    Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study.
    Pfohl M; Seufert J; Borck A; Bramlage P; Siegmund T
    Diabetes Ther; 2021 Mar; 12(3):733-747. PubMed ID: 33544355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study.
    Seufert J; Pfohl M; Borck A; Bramlage P; Siegmund T
    Diabetes Ther; 2021 Mar; 12(3):749-764. PubMed ID: 33544356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.
    Dennis JM; Henley WE; McGovern AP; Farmer AJ; Sattar N; Holman RR; Pearson ER; Hattersley AT; Shields BM; Jones AG;
    Diabetes Obes Metab; 2019 Jul; 21(7):1576-1584. PubMed ID: 30828962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study.
    Zhang YL; Zhou C; Li XF; Yang MN; Tao L; Zheng XY; Jia YS
    Obes Sci Pract; 2019 Aug; 5(4):366-375. PubMed ID: 31452921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association Between Mean Glycated Haemoglobin or Glycaemic Variability and the Development of Retinopathy in People with Diabetes: A Retrospective Observational Cohort Study.
    Dhatariya K; Humberstone A; Hasnat A; Wright R; Lujan M; Nunney I
    Diabetes Ther; 2021 Oct; 12(10):2755-2766. PubMed ID: 34491530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
    Gomes MB; Rathmann W; Charbonnel B; Khunti K; Kosiborod M; Nicolucci A; Pocock SJ; Shestakova MV; Shimomura I; Tang F; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Ji L;
    Diabetes Res Clin Pract; 2019 May; 151():20-32. PubMed ID: 30904743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.